Kuros Biosciences AG (CSBTF) Dividendos

Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. The company is headquartered in Schlieren, Zuerich and currently employs 178 full-time employees. The company went IPO on 2002-10-29. The firm's key product is MagnetOs, which is a synthetic bone graft technology available in multiple formats such as granules or putty. MagnetOs is designed to stimulate bone formation, including through mechanisms that engage the body’s immune response. The technology behind MagnetOs is associated with osteoimmunology, which involves immune‑modulated bone healing. MagnetOs uses the proprietary NeedleGrip submicron surface technology, which supports bone growth by enhancing biological responses related to healing. The company is indicated for use across the skeletal system and is positioned as a bone graft option for procedures involving various anatomical regions.